Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis

Background and Aims: Nucleotide‐binding oligomerization domain‐like receptor‐family pyrin domain‐containing 3 (NLRP3) inflammasome activation has been shown to result in liver fibrosis. Mechanisms and downstream signaling remain incompletely understood. Here, we studied the role of IL‐18 in hepatic stellate cells (HSCs), and its impact on liver fibrosis. Approach and Results: We observed significantly increased serum levels of IL‐18 (128.4 pg/ml vs. 74.9 pg/ml) and IL‐18 binding protein (BP; 46.50 ng/ml vs. 15.35 ng/ml) in patients with liver cirrhosis compared with healthy controls. Single cell RNA sequencing data showed that an immunoregulatory subset of murine HSCs highly expresses Il18 and Il18r1. Treatment of cultured primary murine HSC with recombinant mouse IL‐18 accelerated their transdifferentiation into myofibroblasts. In vivo, IL‐18 receptor‐deficient mice had reduced liver fibrosis in a model of fibrosis induced by HSC‐specific NLRP3 overactivation. Whole liver RNA sequencing analysis from a murine model of severe NASH‐induced fibrosis by feeding a choline‐deficient, L‐amino acid‐defined, high fat diet showed that genes related to IL‐18 and its downstream signaling were significantly upregulated, and Il18 −/− mice receiving this diet for 10 weeks showed protection from fibrotic changes with decreased number of alpha smooth muscle actin‐positive cells and collagen deposition. HSC activation triggered by NLRP3 inflammasome activation was abrogated when IL‐18 signaling was blocked by its naturally occurring antagonist IL‐18BP. Accordingly, we observed that the severe inflammatory phenotype associated with myeloid cell‐specific NLRP3 gain‐of‐function was rescued by IL‐18BP. Conclusions: Our study highlights the role of IL‐18 in the development of liver fibrosis by its direct effect on HSC activation identifying IL‐18 as a target to treat liver fibrosis.

[1]  S. Ogawa,et al.  A Possible Association Between a Nucleotide‐Binding Domain LRR‐Containing Protein Family PYD‐Containing Protein 1 Mutation and an Autoinflammatory Disease Involving Liver Cirrhosis , 2021, Hepatology.

[2]  H. Zischka,et al.  IL-18 But Not IL-1 Signaling Is Pivotal for the Initiation of Liver Injury in Murine Non-Alcoholic Fatty Liver Disease , 2020, International journal of molecular sciences.

[3]  F. Jamali,et al.  Single dose pharmacokinetics and bioavailability of glucosamine in the rat. , 2002, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[4]  D. Schuppan,et al.  Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer , 2019, American journal of physiology. Gastrointestinal and liver physiology.

[5]  F. Tacke,et al.  Single Cell RNA Sequencing Identifies Subsets of Hepatic Stellate Cells and Myofibroblasts in Liver Fibrosis , 2019, Cells.

[6]  F. Negro,et al.  Interleukin-1 Receptor Antagonist Modulates Liver Inflammation and Fibrosis in Mice in a Model-Dependent Manner , 2019, International journal of molecular sciences.

[7]  R. Schwabe,et al.  NLR Family Pyrin Domain‐Containing 3 Inflammasome Activation in Hepatic Stellate Cells Induces Liver Fibrosis in Mice , 2019, Hepatology.

[8]  Lin Wang,et al.  Neutralization of IL-18 by IL-18 binding protein ameliorates bleomycin-induced pulmonary fibrosis via inhibition of epithelial-mesenchymal transition. , 2019, Biochemical and biophysical research communications.

[9]  Han-bing Wang,et al.  Inhibition of IL-18 reduces renal fibrosis after ischemia-reperfusion. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[10]  G. Kaplanski Interleukin‐18: Biological properties and role in disease pathogenesis , 2017, Immunological reviews.

[11]  F. Spertini,et al.  Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease , 2017, Annals of the rheumatic diseases.

[12]  W. Gao,et al.  IL-18 cleavage triggers cardiac inflammation and fibrosis upon &bgr;-adrenergic insult , 2018, European heart journal.

[13]  A. Wree,et al.  NLRP3 inflammasome driven liver injury and fibrosis: Roles of IL‐17 and TNF in mice , 2018, Hepatology.

[14]  S. Friedman,et al.  Mechanisms of hepatic stellate cell activation , 2017, Nature Reviews Gastroenterology &Hepatology.

[15]  K. Schroder,et al.  NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. , 2017, Journal of hepatology.

[16]  A. Gerbes,et al.  Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4(-/-) mouse model. , 2016, World journal of hepatology.

[17]  Haitao Guo,et al.  Inflammasomes: mechanism of action, role in disease, and therapeutics , 2015, Nature Medicine.

[18]  A. Regev,et al.  Spatial reconstruction of single-cell gene expression data , 2015 .

[19]  M. Shirakawa,et al.  The structural basis for receptor recognition of human interleukin-18 , 2014, Nature Communications.

[20]  A. Wree,et al.  NLRP3 inflammasome activation is required for fibrosis development in NAFLD , 2014, Journal of Molecular Medicine.

[21]  A. Wree,et al.  NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice , 2014, Hepatology.

[22]  James L. Mueller,et al.  Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies. , 2013, The Journal of clinical investigation.

[23]  D. Stainier,et al.  Hepatic stellate cells in liver development, regeneration, and cancer. , 2013, The Journal of clinical investigation.

[24]  C. Tanaka,et al.  An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis , 2013, International journal of experimental pathology.

[25]  M. Idzko,et al.  IL‐18 associates to microvesicles shed from human macrophages by a LPS/TLR‐4 independent mechanism in response to P2X receptor stimulation , 2012, European journal of immunology.

[26]  R. Schwabe,et al.  Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. , 2012, Gastroenterology.

[27]  Christopher K. Glass,et al.  Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis , 2012, Proceedings of the National Academy of Sciences.

[28]  A. Feldstein,et al.  Caspase 1-mediated regulation of fibrogenesis in diet-induced steatohepatitis , 2011, Laboratory Investigation.

[29]  K. Meldrum,et al.  IL-18 neutralization ameliorates obstruction-induced epithelial-mesenchymal transition and renal fibrosis. , 2009, Kidney international.

[30]  D. Kastner,et al.  Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. , 2009, Immunity.

[31]  K. Wallace,et al.  Interleukin-1 participates in the progression from liver injury to fibrosis. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[32]  H. Tilg,et al.  Elevated systemic levels of free interleukin-18 (IL-18) in patients with Crohn's disease. , 2005, European cytokine network.

[33]  M. Miyazaki,et al.  Interleukin 18 causes hepatic ischemia/reperfusion injury by suppressing anti‐inflammatory cytokine expression in mice , 2004, Hepatology.

[34]  H. Tilg,et al.  Plasma Levels of Interleukin-18 and Interleukin-18 Binding Protein Are Elevated in Patients with Chronic Liver Disease , 2002, Journal of Clinical Immunology.

[35]  Masafumi Koga,et al.  Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. , 2003, Metabolism: clinical and experimental.

[36]  Tom Boone,et al.  IL-18-Binding Protein Protects Against Lipopolysaccharide- Induced Lethality and Prevents the Development of Fas/Fas Ligand-Mediated Models of Liver Disease in Mice , 2001, The Journal of Immunology.

[37]  J. Losy,et al.  IL‐18 in patients with multiple sclerosis , 2001, Acta neurologica Scandinavica.

[38]  G. Fantuzzi,et al.  A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. , 2001, Cytokine.

[39]  S. Akira,et al.  Lipopolysaccharide-Induced IL-18 Secretion from Murine Kupffer Cells Independently of Myeloid Differentiation Factor 88 That Is Critically Involved in Induction of Production of IL-12 and IL-1β1 , 2001, The Journal of Immunology.

[40]  V. Mehta,et al.  ATP-stimulated Release of Interleukin (IL)-1β and IL-18 Requires Priming by Lipopolysaccharide and Is Independent of Caspase-1 Cleavage* , 2001, The Journal of Biological Chemistry.

[41]  T. Tanimoto,et al.  Interferon-gamma-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. , 2001, Arthritis and rheumatism.

[42]  T. Tanimoto,et al.  Serum interferon‐gamma‐inducing factor/IL‐18 levels in primary biliary cirrhosis , 2000, Clinical and experimental immunology.

[43]  T. Tanimoto,et al.  Elevation of serum interleukin-18 levels and activation of Kupffer cells in biliary atresia. , 2000, Journal of pediatric surgery.

[44]  L. Joosten,et al.  Neutralization of IL-18 Reduces Neutrophil Tissue Accumulation and Protects Mice Against Lethal Escherichia coli and Salmonella typhimurium Endotoxemia1 , 2000, The Journal of Immunology.

[45]  M Eisenstein,et al.  Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Wilcox,et al.  Human keratinocytes constitutively express interleukin-18 and secrete biologically active interleukin-18 after treatment with pro-inflammatory mediators and dinitrochlorobenzene. , 1999, The Journal of investigative dermatology.

[47]  G. Fantuzzi,et al.  Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1beta are differentially regulated in human blood mononuclear cells and mouse spleen cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[48]  C. Moskaluk,et al.  IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. , 1998, Journal of immunology.

[49]  T. Born,et al.  Cloning of a Novel Receptor Subunit, AcPL, Required for Interleukin-18 Signaling* , 1998, The Journal of Biological Chemistry.

[50]  H. Okamura,et al.  Propionibacterium acnes treatment diminishes CD4+ NK1.1+ T cells but induces type I T cells in the liver by induction of IL-12 and IL-18 production from Kupffer cells. , 1997, Journal of immunology.

[51]  R. Kamen,et al.  Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. , 1997, Nature.

[52]  H. Okamura,et al.  Cloning of a new cytokine that induces IFN-gamma production by T cells. , 1995, Nature.